PSNL
Personalis, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$17.20
+2.20%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−17.1x
Market Cap
$1.84B
MomentumView details →
1D Return
+2.20%
YTD Return
+111.60%
RSI (14)
61.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−17.1x
Market Cap
$1.84B
RSI (14)
61.0
MomentumView details →
1D Return
+2.20%
YTD Return
+111.60%
SummaryUpdated Jun 1, 2026
Personalis, Inc. (NASDAQ:PSNL) is a cancer genomics company founded in 2011 and headquartered in Menlo Park, California. The company went public in June 2019 and specializes in providing advanced genomic sequencing and data analysis services to support cancer therapy development and large-scale genetic research programs. Personalis has evolved from a broad genomics services provider to focus primarily on minimal residual disease (MRD) testing, a rapidly growing field in cancer diagnostics that helps detect microscopic amounts of cancer remaining after treatment.
Similar companies
Latest newsMore news →
Personalis reported a Q2 2026 net loss of $0.30 per share, missing the Zacks Consensus Estimate of a $0.25 loss and wider than the $0.23 loss a year earlier.31d agoWohl & Fruchter LLP announced an investigation into the fairness of the proposed acquisition of Personalis, Inc. by Tempus AI, Inc. for $16.25 per share.31d agoTEMPUS AI will acquire PERSONALIS at $16.25 per share, with the transaction expected to close between late 2026 and early 2027.46d ago